Botulinum toxin treatment of pes cavovarus in a child suffering from autosomal recessive axonal Charcot-Marie-Tooth neuropathy (AR-CMT2)

European Journal of Physical and Rehabilitation Medicine

Volumn 51, Issue 3, 2015, Pages 345-349

  Tiffreau, V ^a   Allart, E ^a   Dangleterre, C ^a   Boutry, N ^a   Petit, F ^a   Cuisset, J M ^a   Thevenon, A ^a  

^a UNIV LILLE   (France)

Author keywords

Botulinum toxin ; Charcot Marie Tooth disease ; Gait; Injections

Indexed keywords

BOTULINUM TOXIN; NEUROTOXIN;

CASE REPORT; CHARCOT-MARIE-TOOTH DISEASE; COMPLICATION; FEMALE; FOOT DEFORMITIES; GAIT; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; PRESCHOOL CHILD;

BOTULINUM TOXINS; CHARCOT-MARIE-TOOTH DISEASE; CHILD, PRESCHOOL; FEMALE; FOOT DEFORMITIES; GAIT; HUMANS; NEUROTOXINS;

EID: 84932123850     PISSN: 19739087     EISSN: 19739095     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Martyn CN, Hughes RA. Epidemiology of peripheral neuropathy. J Neurol. Neurosurg Psychiatry 1997;62:310-8.
2. Wicart P. Cavus foot, from neonates to adolescents. Orthop. Traumatol. Surg. Res. 2012;98:813-28.
3. Karakis I, Gregas M, Darras BT, Kang PB, Jones HR. Clinical correlates of Charcot-Marie-Tooth disease in patients with pes cavus deformities. Muscle Nerve. 2013;47:488-92.
4. Burns J, Ryan MM, Ouvrier RA. Evolution of foot and ankle manifestations in children with CMT1A. Muscle Nerve. 2009;39:158-66.
5. Saporta ASD, Sottile SL, Miller LJ, Feely SME, Siskind CE, Shy ME. Charcot Marie Tooth (CMT) Subtypes and Genetic Testing Strategies. Ann. Neurol. 2011;69:22-33.
6. Tazir M, Bellatache M, Nouioua S, Vallat J-M. Autosomal recessive Charcot-Marie-Tooth disease: from genes to phenotypes. J. Peripher. Nerv. Syst. 2013;18:113-29.
7. Pareyson D, Marchesi C. Diagnosis, natural history, and management of Charcot-Marie-Tooth disease. Lancet Neurol. 2009;8:654-67.
8. Berciano J, Sevilla T, Casasnovas C, Sivera R, Vílchez JJ, Infante J et al. Guidelines for molecular diagnosis of Charcot-Marie-Tooth disease. Neurol Engl Ed 2012;27:169-78.
9. Li J. Inherited Neuropathies. Semin Neurol 2012;32:204-14.
10. Claramunt R, Pedrola L, Sevilla T, d Lopez, Berciano J, Cuesta A et al. Genetics of Charcot-Marie-Tooth disease type 4A: mutations, inheritance, phenotypic variability, and founder effect. J Med Genet 2005;42:358-65.
11. Compston A. Aids to the Investigation of Peripheral Nerve Injuries. Medical Research Council: Nerve Injuries Research Committee. His Majesty's Stationery Office: 1942; pp. 48 (iii) and 74 figures and 7 diagrams; with Aids to the Examination of the Peripheral Nervous System. By Michael O'Brien for the Guarantors of Brain. Saunders Elsevier: 2010; pp. [8] 64 and 94 Figures. Brain 2010;133:2838-44.
12. De Muynck M, Parlevliet T, De Cock K, Vanden Bossche L, Vanderstraeten G, Özçakar L. Musculoskeletal ultrasound for interventional physiatry. Eur J Phys Rehabil Med 2012;48:675-87.
13. Ozçakar L, Carli AB, Tok F, Tekin L, Akkaya N, Kara M. The utility of musculoskeletal ultrasound in rehabilitation settings. Am J Phys Med Rehabil Assoc Acad Physiatr 2013;92:805-17.
14. Coffield JA. Botulinum neurotoxin: the neuromuscular junction revisited. Crit. Rev. Neurobiol 2003;15:175-96.
15. Biuk D, Karin AA, Matić S, Barać J, Benasić T, Stiglmayer N. Quality of life in patients with blepharospasm. Coll Antropol 2013;37:29-33.
16. Novak I, Campbell L, Boyce M, Fung VSC, Cerebral Palsy Institute. Botulinum toxin assessment, intervention and aftercare for cervical dystonia and other causes of hypertonia of the neck: international consensus statement. Eur J Neurol 2010;17(Suppl 2):94-108.
17. Sheean G, Lannin NA, Turner-Stokes L, Rawicki B, Snow BJ, Cerebral Palsy Institute. Botulinum toxin assessment, intervention and after-care for upper limb hypertonicity in adults: international consensus statement. Eur J Neurol 2010;17(Suppl 2):74-93.
18. Baker JA, Pereira G. The efficacy of Botulinum Toxin A for spasticity and pain in adults: a systematic review and meta-analysis using the Grades of Recommendation, Assessment, Development and Evaluation approach. Clin Rehabil 2013;27:1084-96.
19. Burns J, Scheinberg A, Ryan MM, Rose KJ, Ouvrier RA. Randomized trial of botulinum toxin to prevent pes cavus progression in pediatric Charcot-Marie-Tooth disease type 1A. Muscle Nerve 2010;42:262-7.
20. Bird TD. Charcot-Marie-Tooth Neuropathy Type 4 [Internet]. In: Pagon RA, Adam MP, Bird TD, Dolan CR, Fong C-T, Stephens K, editors. GeneReviews™. Seattle (WA): University of Washington, Seattle; 1993 [Internet]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1468/ [cited 2013, Jul 23].
21. Vital A, Vital C. Mitochondria and peripheral neuropathies. J. Neuropathol Exp Neurol 2012;71:1036-46.